The Role Of Maintenance Therapy after SCT - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

The Role Of Maintenance Therapy after SCT

The Role Of Maintenance Therapy after SCT image

The Role Of Maintenance Therapy after SCT

Webinar
event Aug 31, 2022 / 01:00PM - 02:00PM EDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Why is maintenance therapy so strongly recommended after a stem cell transplant? How long do physicians wait to give maintenance therapy after the procedure? For how long is the maintenance therapy given? Learn the answers to these questions and more as we meet with Dr. Samuel Rubinstein who will share with us his professional opinion. 

Schedule & Agenda

The panelist Audrey Burton-Bethke
01:00 PM
Introduction
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Samuel Rubinstein
The panelist Dr. Samuel Rubinstein
01:05 PM
Presentation
Dr. Samuel Rubinstein
Dr. Samuel Rubinstein shares his professional opinion on the role of maintenance therapy after stem cell transplant.
The panelist Audience
01:35 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Dr. Samuel Rubinstein
Dr. Samuel Rubinstein

Dr. Rubinstein is an assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias. During the COVID-19 pandemic, Dr. Rubinstein also developed an interest in the impacts of COVID-19 on patients with cancer. He serves as the site PI of the COVID-19 and cancer consortium (CCC19) at UNC, and in this capacity has contributed to a number of studies derived from CCC-19 data to answer clinically relevant questions about the epidemiology and outcomes of patients with cancer and COVID-19.

Read Bio
HealthTree Connect Icon

Join the Conversation

This event is part of the Stem Cell Transplant group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.